D-1840-2019 Class III Terminated
FDA drug recall D-1840-2019 was initiated by Akorn, Inc. on Aug 6, 2019 and is designated Class III. Reason for recall: Short Fill: fill volume was out of specification at 94 mL (specification: no less than 100 mL) and Failed Impurities/Degradation Specifications: Out of Specification (OOS) for known impurity… The recall status is terminated (terminated Jul 28, 2022). Affected quantity: 648 vials.
Recall details
- Product Type
- Drugs
- Report Date
- Sep 4, 2019
- Initiation Date
- Aug 6, 2019
- Termination Date
- Jul 28, 2022
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 648 vials
Product description
Eptifibatide Injection, 75 mg/100 mL (0.75 mg/mL), 100 mL Single-use Vial, For Intravenous Use Only, Rx Only, Manufactured by: Akorn Inc., Lake Forest, IL 60045, NDC 17478-903-90.
Reason for recall
Short Fill: fill volume was out of specification at 94 mL (specification: no less than 100 mL) and Failed Impurities/Degradation Specifications: Out of Specification (OOS) for known impurity, D-aspartic acid.
Distribution pattern
Nationwide in the U.S.
Code information
Lot #: 101107A, Exp. 10/19.
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-1840-2019
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026